WO1999005266B1 - Transfert de noyau entre des especes differentes - Google Patents
Transfert de noyau entre des especes differentesInfo
- Publication number
- WO1999005266B1 WO1999005266B1 PCT/US1998/015387 US9815387W WO9905266B1 WO 1999005266 B1 WO1999005266 B1 WO 1999005266B1 US 9815387 W US9815387 W US 9815387W WO 9905266 B1 WO9905266 B1 WO 9905266B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- nuclear transfer
- donor
- hours
- enucleated
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims abstract 20
- 238000000034 method Methods 0.000 claims abstract 17
- 210000000287 oocyte Anatomy 0.000 claims abstract 16
- 241000283690 Bos taurus Species 0.000 claims abstract 9
- 241000894007 species Species 0.000 claims abstract 9
- 210000002257 embryonic structure Anatomy 0.000 claims abstract 4
- 210000002966 serum Anatomy 0.000 claims abstract 3
- 238000012258 culturing Methods 0.000 claims abstract 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 230000006370 G0 arrest Effects 0.000 claims 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 210000000805 cytoplasm Anatomy 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 210000001082 somatic cell Anatomy 0.000 claims 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 210000003855 cell nucleus Anatomy 0.000 claims 1
- 230000003028 elevating effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8771—Bovine embryos
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU85875/98A AU8587598A (en) | 1997-07-26 | 1998-07-24 | Trans-species nuclear transfer |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5310397P | 1997-07-26 | 1997-07-26 | |
| US60/053,103 | 1997-07-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999005266A2 WO1999005266A2 (fr) | 1999-02-04 |
| WO1999005266A3 WO1999005266A3 (fr) | 1999-04-15 |
| WO1999005266B1 true WO1999005266B1 (fr) | 1999-09-23 |
Family
ID=21981947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/015387 WO1999005266A2 (fr) | 1997-07-26 | 1998-07-24 | Transfert de noyau entre des especes differentes |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU8587598A (fr) |
| WO (1) | WO1999005266A2 (fr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US7696404B2 (en) | 1996-08-19 | 2010-04-13 | Advanced Cell Technology, Inc. | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| EP0934403A4 (fr) * | 1996-08-19 | 2001-03-14 | Univ Massachusetts | Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes |
| IL138201A0 (en) * | 1998-03-02 | 2001-10-31 | Univ Massachusetts | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation |
| JP2002511234A (ja) * | 1998-03-16 | 2002-04-16 | リレグ ピーティーワイ リミテッド | ブタの核移植 |
| US7621606B2 (en) | 2001-08-27 | 2009-11-24 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| CA2334953A1 (fr) * | 1999-06-30 | 2001-01-04 | Woo-Suk Hwang | Procede d'obtention d'embryons humains clones au moyen de techniques de transplantation inter-especes de noyaux |
| BR0012099A (pt) | 1999-06-30 | 2003-07-29 | Advanced Cell Tech Inc | Transferência citoplásmica para de-diferenciar células recipientes |
| CN1304443A (zh) * | 1999-06-30 | 2001-07-18 | 黄禹锡 | 一种生产克隆牛的方法 |
| NZ508739A (en) * | 1999-06-30 | 2002-11-26 | Woo Suk Hwang | Method for producing cloned tigers by employing inter-species nuclear transplantation technique |
| IL148547A0 (en) * | 1999-09-14 | 2002-09-12 | Univ Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| CA2394614A1 (fr) * | 1999-12-20 | 2001-06-28 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Cellules souches ou embryonnaires produites par transplantation nucleaire heterospecifique |
| EP1984487B1 (fr) | 2005-08-03 | 2022-10-12 | Astellas Institute for Regenerative Medicine | Procedes ameliores de reprogrammation de cellules somatiques animales |
| WO2013010045A1 (fr) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Nouveaux procédés et formulations pour thérapie cellulaire orthopédique |
| KR102186281B1 (ko) | 2013-04-16 | 2020-12-03 | 리제너론 파마슈티칼스 인코포레이티드 | 랫트 게놈의 표적화된 변형 |
| PT3080279T (pt) | 2013-12-11 | 2018-12-17 | Regeneron Pharma | Métodos e composições para a modificação direcionada de um genoma |
| JP6174811B2 (ja) | 2013-12-11 | 2017-08-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ゲノムの標的改変のための方法及び組成物 |
| JP6688231B2 (ja) | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 標的遺伝子座を修飾するための方法及び組成物 |
| SG10201911411YA (en) | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| AU2015349692B2 (en) | 2014-11-21 | 2021-10-28 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide RNAs |
| BR112017013104A2 (pt) | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| KR102424119B1 (ko) | 2015-03-16 | 2022-07-25 | 리제너론 파마슈티칼스 인코포레이티드 | 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물 |
| MX380603B (es) | 2015-05-29 | 2025-03-12 | Regeneron Pharma | Animales no humanos que tienen una alteracion en un locus de c9orf72. |
| CN109195443A (zh) | 2016-02-16 | 2019-01-11 | 雷杰纳荣制药公司 | 具有突变型犬尿氨酸酶基因的非人动物 |
| KR102356542B1 (ko) | 2016-05-20 | 2022-01-28 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
| US10548302B2 (en) | 2016-07-29 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy |
| ES3000677T3 (en) | 2016-09-30 | 2025-03-03 | Regeneron Pharma | Rodents having a hexanucleotide repeat expansion in a c9orf72 locus |
| SG11201907490XA (en) | 2017-02-27 | 2019-09-27 | Regeneron Pharma | Non-human animal models of retinoschisis |
| US11696572B2 (en) | 2017-06-27 | 2023-07-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ASGR1 locus |
| BR112019027673A2 (pt) | 2017-07-31 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | animal não humano, e, métodos para testar a recombinação induzida por crispr/cas e para otimizar a capacidade de crispr/cas |
| CN110891420B (zh) | 2017-07-31 | 2022-06-03 | 瑞泽恩制药公司 | Cas转基因小鼠胚胎干细胞和小鼠及其应用 |
| MX2020001177A (es) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Animales no humanos reporteros de crispr y usos de los mismos. |
| SG11202000771UA (en) | 2017-09-29 | 2020-04-29 | Regeneron Pharma | Non-human animals comprising a humanized ttr locus and methods of use |
| JP7097440B2 (ja) | 2017-11-10 | 2022-07-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Slc30a8変異を含む非ヒト動物および使用方法 |
| CN111655031B (zh) | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| CA3089331A1 (fr) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Modulation de la transcription chez des animaux a l'aide de systemes crispr/cas |
| KR102545031B1 (ko) | 2018-09-13 | 2023-06-20 | 리제너론 파마슈티칼스 인코포레이티드 | C3 사구체병증 모델로서의 보체 인자 h 유전자 녹아웃 래트 |
| SG11202105189RA (en) | 2018-12-20 | 2021-06-29 | Regeneron Pharma | Nuclease-mediated repeat expansion |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子12遺伝子座を含む非ヒト動物 |
| CA3137761A1 (fr) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus ttr humanise ayant une mutation beta-slip et procedes d'utilisation |
| MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
| EP3990475A1 (fr) | 2019-06-27 | 2022-05-04 | Regeneron Pharmaceuticals, Inc. | Modélisation de la protéinopathie à tdp-43 |
| WO2021108363A1 (fr) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Régulation à la hausse médiée par crispr/cas d'un allèle ttr humanisé |
| CA3169272A1 (fr) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus pnpla3 humanise et procedes d'utilisation |
| WO2021158883A1 (fr) | 2020-02-07 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus klkb1 humanisé et procédés d'utilisation |
| EP4125348A1 (fr) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant un locus ttr humanisé affichant une mutation v30m et méthodes d'utilisation |
| US20230232796A1 (en) | 2020-06-26 | 2023-07-27 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| CN118488784A (zh) | 2021-11-04 | 2024-08-13 | 瑞泽恩制药公司 | 包含经修饰的cacng1基因座的非人动物 |
| KR20240117571A (ko) | 2021-12-08 | 2024-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 돌연변이 마이오실린 질환 모델 및 이의 용도 |
| CN113943712B (zh) * | 2021-12-20 | 2022-03-22 | 南京岚轩生物科技有限公司 | 一种电融合缓冲液、其制备方法及电融合方法 |
| WO2023122506A1 (fr) | 2021-12-20 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Animaux non humains comprenant des loci ace2 et tmprss humanisés |
| WO2023150798A1 (fr) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés permettant de définir des délais de traitement optimaux dans le cadre d'une maladie lysosomale |
| WO2023154861A1 (fr) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés de criblage d'agents de ciblage de tau 4r |
| WO2023235677A1 (fr) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Modèle animal de protéinopathie tdp-43 |
| CN120112164A (zh) | 2022-07-29 | 2025-06-06 | 瑞泽恩制药公司 | 包含修饰的转铁蛋白受体基因座的非人动物 |
| IL318553A (en) | 2022-08-05 | 2025-03-01 | Regeneron Pharma | Aggregation-resistant TDP-43 variants |
| WO2024073679A1 (fr) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction de la stéatose hépatique chez des animaux hépatiques humanisés par restauration de la signalisation il6/il6r/gp130 dans des hépatocytes humains |
| WO2024163650A1 (fr) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Animaux comprenant un locus klhdc7b modifié |
| WO2025006963A1 (fr) | 2023-06-30 | 2025-01-02 | Regeneron Pharmaceuticals, Inc. | Procédés et compositions pour augmenter la réparation dirigée par homologie |
| WO2025122754A1 (fr) | 2023-12-07 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Animaux non humains knockout pour gaa |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496720A (en) * | 1993-02-10 | 1996-03-05 | Susko-Parrish; Joan L. | Parthenogenic oocyte activation |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| EP0934403A4 (fr) * | 1996-08-19 | 2001-03-14 | Univ Massachusetts | Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
-
1998
- 1998-07-24 AU AU85875/98A patent/AU8587598A/en not_active Abandoned
- 1998-07-24 WO PCT/US1998/015387 patent/WO1999005266A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999005266A2 (fr) | 1999-02-04 |
| WO1999005266A3 (fr) | 1999-04-15 |
| AU8587598A (en) | 1999-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1999005266B1 (fr) | Transfert de noyau entre des especes differentes | |
| Cheong et al. | Birth of mice after transplantation of early cell-cycle-stage embryonic nuclei into enucleated oocytes | |
| Tsunoda et al. | Full‐term development of mouse blastomere nuclei transplanted into enucleated two‐cell embryos | |
| EP0739412B1 (fr) | CELLULES d'ongules, SOUCHES D'EMBRYONS UTILISEES COMME DONNEUSES DE NOYAUX ET PROCEDES DE TRANSFERT DE NOYAUX POUR LA PRODUCTION D'ANIMAUX CHIMERIQUES ET TRANSGENIQUES | |
| Fulka Jr et al. | Nuclear transplantation in mammals: remodelling of transplanted nuclei under the influence of maturation promoting factor | |
| Smith et al. | Influence of cell cycle stage at nuclear transplantation on the development in vitro of mouse embryos | |
| Prather et al. | Nuclear transplantation in the pig embryo: nuclear swelling | |
| Kragh et al. | Efficient in vitro production of porcine blastocysts by handmade cloning with a combined electrical and chemical activation | |
| JP2001509361A5 (fr) | ||
| Niu et al. | Distribution and content of lipid droplets and mitochondria in pig parthenogenetically activated embryos after delipation | |
| Roh et al. | Technical report: In vitro development of porcine parthenogenetic and cloned embryos: comparison of oocyte-activating techniques, various culture systems and nuclear transfer methods | |
| Yamamoto et al. | Production of mouse offspring from inactivated spermatozoa using horse PLCζ mRNA | |
| Smith et al. | Factors affecting the viability of nuclear transplanted-embryos | |
| Renard | Chromatin remodelling and nuclear reprogramming at the onset of embryonic development in mammals | |
| Miki et al. | Cytoplasmic asters are required for progression past the first cell cycle in cloned mouse embryos | |
| Riaz et al. | Mouse cloning and somatic cell reprogramming using electrofused blastomeres | |
| Meena et al. | Development of water buffalo (Bubalus bubalis) embryos from in vitro matured oocytes reconstructed with fetal skin fibroblast cells as donor nuclei | |
| Hirabayashi et al. | Factors influencing chromosome condensation and development of cloned rat embryos | |
| Savy et al. | Effect of embryo aggregation on in vitro development of adipose-derived mesenchymal stem cell-derived bovine clones | |
| AU777799B2 (en) | Telophase enucleated oocytes for nuclear transfer | |
| Lu et al. | Reconstruction of human embryos derived from somatic cells | |
| Stice et al. | Progress towards efficient commercial embryo cloning | |
| Vichera et al. | Oocyte genome cloning used in biparental bovine embryo reconstruction | |
| AU3391093A (en) | Bovine nuclear transplantation | |
| Betthauser et al. | The use of Hoechst 33342 to stain donor nuclei used in the bovine nuclear transfer procedure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09463276 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: CA |